Education
About Us
Working with TipRanks
Follow Us
Novartis AG (DE:NOTA)
:NOTA
Earnings Data
Report Date
Oct 28, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
1.91Last Year’s EPS
1.76Same Quarter Last Year
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted a strong quarter with robust sales and operating income growth, driven by key products like Kisqali, Kesimpta, and Leqvio. New buyback programs and continued pipeline advancements also contributed positively. However, challenges such as Cosentyx's moderated growth, a slowdown in China, and potential generic threats in the U.S. were notable concerns.Company Guidance -
Q3 2025
Strong Sales and Operating Income Growth
Sales were up 11% in constant currency, and core operating income increased by 21% in constant currency for Q2 2025.
Kisqali's Robust Performance
Kisqali grew 64% in the quarter, achieving TRx leadership in metastatic breast cancer, with a 100% increase in the U.S. in Q2.
New Buyback Program
Initiation of a new up to $10 billion share buyback program targeted for completion by the end of 2027.
Kesimpta's Growth Trajectory
Kesimpta grew 33% in the quarter, with strong demand growth for a self-administered B-cell therapy for MS.
Leqvio's Strong Growth
Leqvio grew 61% in the quarter, driven by outpacing the lipid-lowering market in the U.S. and strong growth in China.
Scemblix's Expansion
Scemblix saw 79% constant currency growth and is on track to exceed $1 billion in sales, with growing momentum in early lines.
DE:NOTA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:NOTA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jul 17, 2025 | €100.50 | €104.00 | +3.48% |
Apr 29, 2025 | €99.20 | €101.00 | +1.81% |
Jan 31, 2025 | €94.11 | €97.99 | +4.12% |
Oct 29, 2024 | €100.42 | €98.48 | -1.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Novartis AG (DE:NOTA) report earnings?
Novartis AG (DE:NOTA) is schdueled to report earning on Oct 28, 2025, TBA (Confirmed).
What is Novartis AG (DE:NOTA) earnings time?
Novartis AG (DE:NOTA) earnings time is at Oct 28, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Novartis AG stock?
The P/E ratio of Novartis is N/A.
What is DE:NOTA EPS forecast?
DE:NOTA EPS forecast for the fiscal quarter 2025 (Q3) is 1.91.
